Abbott EVP Morrone sells 1,144 company shares

Abbott Laboratories executive Louis H. Morrone reported selling 1,144 common shares in an open‑market transaction at $115.58 per share on March 2, 2026.

Rhea-AI Filing Summary

Abbott Laboratories executive Louis H. Morrone reported selling 1,144 common shares in an open‑market transaction at $115.58 per share on March 2, 2026. After this sale, his directly held stake was 76,843 common shares.

On February 27, 2026, 4,040 common shares were disposed of at $116.26 per share to cover tax withholding obligations rather than as an open‑market sale. The filing also notes 12 common shares held indirectly through a Profit Sharing Trust as of February 27, 2026.

Insider Trade Summary

Net Seller: 1,144 shares

Net Sell 3 txns

Insider Morrone Louis H.

Role EXECUTIVE VICE PRESIDENT

Sold 1,144 shs ($132K)

Type	Security	Shares	Price	Value
Sale	Common shares without par value	1,144	$115.58	$132K
Exercise Price or Tax Liability	Common shares without par value	4,040	$116.26	$470K
holding	Common shares without par value	--	--	--

Holdings After Transaction: Common shares without par value — 76,843 shares (Direct); Common shares without par value — 12 shares (Indirect, Profit Sharing Trust)

Footnotes (1)

1. F1. Balance in the Abbott Laboratories Stock Retirement Trust as of February 27, 2026.

FAQ

What insider transactions did Abbott (ABT) EVP Louis H. Morrone report?

Louis H. Morrone reported selling 1,144 Abbott common shares in an open‑market transaction at $115.58 per share. He also reported a separate 4,040‑share tax‑withholding disposition at $116.26 per share, both involving Abbott Laboratories common stock.

How many Abbott (ABT) shares did Louis H. Morrone sell in the open market?

Louis H. Morrone sold 1,144 Abbott Laboratories common shares in an open‑market transaction. The reported sale price was $115.58 per share, and it occurred on March 2, 2026, according to the Form 4 insider trading report.

What was the purpose of the 4,040-share transaction in Abbott (ABT) stock?

The 4,040 Abbott common shares were disposed of to satisfy tax withholding obligations. This tax‑withholding disposition, reported at $116.26 per share on February 27, 2026, was not an open‑market sale but a share delivery for tax payment.

How many Abbott (ABT) shares does Louis H. Morrone hold after these transactions?

After the reported transactions, Louis H. Morrone directly held 76,843 Abbott common shares. The filing also notes an additional 12 common shares held indirectly through a Profit Sharing Trust as of February 27, 2026.

What indirect holdings in Abbott (ABT) stock does Louis H. Morrone report?

Louis H. Morrone reports 12 Abbott common shares held indirectly through a Profit Sharing Trust. A footnote states this balance reflects holdings in the Abbott Laboratories Stock Retirement Trust as of February 27, 2026, separate from his direct ownership.

What prices were reported for Louis H. Morrone’s Abbott (ABT) share transactions?

The open‑market sale of 1,144 Abbott common shares was reported at $115.58 per share on March 2, 2026. The 4,040‑share tax‑withholding disposition was reported at $116.26 per share on February 27, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 08:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morrone Louis H.

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXECUTIVE VICE PRESIDENT

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	02/27/2026		F		4,040	D	$116.26	77,987	D
Common shares without par value	03/02/2026		S		1,144	D	$115.58	76,843	D
Common shares without par value								12(1)	I	Profit Sharing Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Balance in the Abbott Laboratories Stock Retirement Trust as of February 27, 2026.

	/s/ Louis H. Morrone by Jessica H. Paik, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.